O'Shaughnessy Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.9M | Sell |
138,260
-3,064
| -2% | -$586K | 0.14% | 157 |
|
|
2026
Q1 | $25.9M | Buy |
141,324
+31,056
| +28% | +$5.72M | 0.13% | 170 |
|
|
2025
Q4 | $19.4M | Buy |
110,268
+50,279
| +84% | +$8.21M | 0.11% | 213 |
|
|
2025
Q3 | $8.4M | Buy |
59,989
+31,677
| +112% | +$4.28M | 0.05% | 373 |
|
|
2025
Q2 | $3.56M | Buy |
28,312
+25,836
| +1,043% | +$3.22M | 0.02% | 575 |
|
|
2025
Q1 | $339K | Buy |
2,476
+806
| +48% | +$115K | ﹤0.01% | 1516 |
|
|
2024
Q4 | $255K | Sell |
1,670
-1,926
| -54% | -$325K | ﹤0.01% | 1618 |
|
|
2024
Q3 | $689K | Sell |
3,596
-1,236
| -26% | -$259K | 0.01% | 1070 |
|
|
2024
Q2 | $1.12M | Buy |
4,832
+892
| +23% | +$194K | 0.01% | 808 |
|
|
2024
Q1 | $849K | Buy |
3,940
+188
| +5% | +$44K | 0.01% | 876 |
|
|
2023
Q4 | $971K | Sell |
3,752
-1,451
| -28% | -$356K | 0.01% | 765 |
|
|
2023
Q3 | $1.34M | Buy |
5,203
+58
| +1% | +$15.5K | 0.02% | 597 |
|
|
2023
Q2 | $1.47M | Buy |
5,145
+249
| +5% | +$74.1K | 0.02% | 535 |
|
|
2023
Q1 | $1.36M | Sell |
4,896
-278
| -5% | -$76.9K | 0.02% | 558 |
|
|
2022
Q4 | $1.43M | Sell |
5,174
-42,734
| -89% | -$12.1M | 0.02% | 500 |
|
|
2022
Q3 | $12.8M | Sell |
47,908
-27,024
| -36% | -$5.74M | 0.24% | 112 |
|
|
2022
Q2 | $15.3M | Buy |
74,932
+12,938
| +21% | +$2.64M | 0.28% | 105 |
|
|
2022
Q1 | $13.1M | Sell |
61,994
-20,318
| -25% | -$4.42M | 0.22% | 123 |
|
|
2021
Q4 | $19.7M | Sell |
82,312
-6,989
| -8% | -$1.8M | 0.35% | 82 |
|
|
2021
Q3 | $25.3M | Sell |
89,301
-4,291
| -5% | -$1.41M | 0.52% | 54 |
|
|
2021
Q2 | $32.4M | Sell |
93,592
-39,445
| -30% | -$11.9M | 0.64% | 41 |
|
|
2021
Q1 | $37.2M | Sell |
133,037
-17,007
| -11% | -$4.59M | 0.82% | 26 |
|
|
2020
Q4 | $36.7M | Sell |
150,044
-76,081
| -34% | -$19.6M | 1% | 22 |
|
|
2020
Q3 | $64.2M | Buy |
226,125
+93,321
| +70% | +$26M | 1.92% | 13 |
|
|
2020
Q2 | $35.5M | Buy |
132,804
+28,631
| +27% | +$8.61M | 1.1% | 29 |
|
|
2020
Q1 | $33M | Buy |
104,173
+83,432
| +402% | +$25.3M | 1.16% | 30 |
|
|
2019
Q4 | $6.15M | Buy |
20,741
+20,734
| +296,200% | +$5.75M | 0.14% | 112 |
|
|
2019
Q3 | $2K | Buy |
7
+6
| +600% | +$1.4K | ﹤0.01% | 854 |
|
|
2019
Q2 | $0 | Buy |
+1
| New | +$231 | ﹤0.01% | 978 |
|
|
2015
Q2 | – | Sell |
-18
| Closed | -$8K | – | 977 |
|
|
2015
Q1 | $8K | Sell |
18
-10,032
| -100% | -$3.95M | ﹤0.01% | 761 |
|
|
2014
Q4 | $3.41M | Sell |
10,050
-2,048
| -17% | -$663K | 0.07% | 186 |
|
|
2014
Q3 | $4M | Sell |
12,098
-10,252
| -46% | -$3.38M | 0.07% | 178 |
|
|
2014
Q2 | $7.05M | Sell |
22,350
-3,530
| -14% | -$1.06M | 0.13% | 133 |
|
|
2014
Q1 | $7.92M | Buy |
25,880
+3,708
| +17% | +$1.18M | 0.16% | 115 |
|
|
2013
Q4 | $6.2M | Buy |
22,172
+756
| +4% | +$196K | 0.13% | 127 |
|
|
2013
Q3 | $5.16M | Buy |
21,416
+12,741
| +147% | +$2.85M | 0.12% | 126 |
|
|
2013
Q2 | $1.87M | Buy |
+8,675
| New | +$1.85M | 0.05% | 245 |
|
Other funds holding BIIB
O'Shaughnessy Asset Management's BIIB Position: Q2 2026 in Review
O'Shaughnessy Asset Management reduced its Biogen (BIIB) stake by 2.2% in Q2 2026, selling an estimated $586K and leaving 138,260 shares worth $29.9M. The position accounts for 0.14% of the portfolio, ranked #157.
O'Shaughnessy Asset Management first reported a position in BIIB in Q2 2013 and has held it in 37 quarters since. The position peaked at $64.2M in Q3 2020. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- O'Shaughnessy Asset Management held 138,260 shares of Biogen worth $29.9M as of Q2 2026.
- O'Shaughnessy Asset Management sold 3,064 Biogen shares in Q2 2026, an estimated $586K.
- Biogen made up 0.14% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #157 holding.
- O'Shaughnessy Asset Management first reported a position in Biogen in Q2 2013 and has held it in 37 quarters since.
- O'Shaughnessy Asset Management's Biogen position peaked at $64.2M in Q3 2020.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.